Acorda Therapeutics (ACOR) 27.07 $ACOR
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), IDRA: 1.50 (-0.07), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)
Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 81.10 (-1.84), ALXN: 135.61 (-2.63), AEGR: 1.37 (-0.13), ACOR: 27.07 (-0.45)
Acorda Presents Phase 1 Data on CVT-427 for Acute Treatment of Migraine at 58th Annual Scientific Meeting of the American Headache Society
BusinessWire - Thu Jun 09, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced pharmacokinetic (PK) data from a Phase 1 study of CVT-427, an inhaled formulation of zolmitriptan, resulting in increased bioavailability and faster absorption compared to oral and nasal administration of the same active ingredient in healthy adults. The data on CVT-427, an investigational agent under development for the acute treatment of migraines, will be presented on June 10th, 2016, at the 58th Annual Scientific Meeting of the American Headache Society, in San Diego, CA.
ACOR: 27.07 (-0.45)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), IDRA: 1.50 (-0.07), RTRX: 17.40 (-0.30), LGND: 113.74 (-1.34), ACOR: 27.07 (-0.45)
Celldex (CLDX) Presents Phase II Melanoma Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 9:45AM CDT
Celldex Therapeutics (CLDX) announced positive phase II data evaluating CDX-301 and CDX-1401 in patients with malignant melanoma at ASCO.
ANIP: 52.05 (-1.64), CLDX: 4.12 (-0.20), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)
Acorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference
BusinessWire - Tue May 31, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 7 at 2:00pm PT (5:00pm ET).
ACOR: 27.07 (-0.45)
The Medicines Co. Carbavance TANGO 1 Study Enrolled
Zacks Equity Research - Zacks Investment Research - Fri May 27, 1:45PM CDT
The Medicines Company (MDCO) announced that it has completed enrollment in the phase III TANGO 1 study on Carbavance for the treatment of cUTI.
MDCO: 37.26 (-1.22), ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)
Alkermes Begins Phase I Study on Immuno-Oncology Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 10:30AM CDT
Alkermes (ALKS) announced the initiation of a phase I study on its immuno-oncology candidate ALKS 4230 for the treatment of solid tumors
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45), ALKS: 42.65 (-1.17)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 91.49 (-1.00), HZNP: 17.88 (-0.65), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25), ACOR: 27.07 (-0.45), BIOD: 0.34 (unch), XNPT: 7.00 (unch)
Acorda Shelves Development of Epilepsy Treatment, Plumiaz
Arpita Dutt - Zacks Investment Research - Mon May 23, 6:39AM CDT
Acorda's (ACOR) decision to terminate the development of Plumiaz was based on data from ongoing studies.
HSKA: 35.56 (-0.56), ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)
Acorda to Discontinue Development of PLUMIAZ for Treatment of Epilepsy Seizure Clusters
BusinessWire - Fri May 20, 5:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will discontinue development of PLUMIAZ(TM) (diazepam) Nasal Spray, an investigational therapy being studied for the treatment of seizure clusters in people with epilepsy. Data from the ongoing clinical trials do not demonstrate its bioequivalence to Diastat(R) rectal gel, needed to re-file the New Drug Application (NDA) under section 505(b)(2). Specifically, the data demonstrated unexpectedly lower nasal mucosa absorption of diazepam in persons with epilepsy compared to studies in healthy volunteers.
ACOR: 27.07 (-0.45)
Biotie Therapies Corp. to Delist Its American Depositary Shares from the Nasdaq Global Select Market
BusinessWire - Wed May 18, 8:00AM CDT
Biotie Therapies Corp. ("Biotie"
today announces that its Board of Directors has resolved to voluntarily delist its American Depositary Shares ("ADSs", each representing 80 Biotie ordinary shares with no nominal value ("Shares", from the NASDAQ Global Select Market ("NASDAQ US".
ACOR: 27.07 (-0.45)
BIOTIE CANCELS ALL TREASURY SHARES HELD BY THE COMPANY
Globe Newswire - Wed May 18, 1:02AM CDT
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 18 May 2016, at 9.00 a.m. (EET)
BITI: 25.80 (-0.71), ACOR: 27.07 (-0.45)
Dry Powder Inhaler Devices Medical Devices Pipeline Assessment, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Acorda Therapeutics, Bespak Europe, Nekta - Research and Markets
BusinessWire - Fri May 13, 9:31AM CDT
Research and Markets has announced the addition of the "Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2016" drug pipelines to their offering.
ACOR: 27.07 (-0.45)
Aegerion Enters into Settlement Agreement with DoJ and SEC
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:36AM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) announced that it has reached preliminary agreements with the U.S. DoJ and staff of the SEC.
ABT: 38.40 (-0.47), AEGR: 1.37 (-0.13), ACOR: 27.07 (-0.45), SNY: 39.41 (-1.45)
Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More
Zacks Equity Research - Zacks Investment Research - Tue May 10, 8:45AM CDT
With the Q1 cycle nearing its end, the earnings picture is becoming increasingly clear. While the going looked tough at the onset of the last month, that scenario has changed over the past few weeks.
CRME: 4.96 (-0.38), JNJ: 117.01 (+0.01), EARS: 3.27 (-0.13), GILD: 84.45 (-1.32), BITI: 25.80 (-0.71), BPTH: 2.43 (-0.01), AMGN: 154.78 (-2.00), ACRS: 21.97 (+0.40), ACOR: 27.07 (-0.45), NVS: 78.94 (-1.57)
Acorda Therapeutics Named One of the Best Places to Work for in New York
BusinessWire - Wed May 04, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the best companies to work for in New York, based on an independent survey by the Best Companies Group (BCG). This is the sixth consecutive year Acorda was among the top 10 best employers in the state.
ACOR: 27.07 (-0.45)
FINAL RESULTS OF THE SUBSEQUENT OFFER PERIOD OF ACORDA'S TENDER OFFER FOR ALL SECURITIES IN BIOTIE
Globe Newswire - Mon May 02, 8:40AM CDT
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 2 May 2016, at 4.40 p.m. (EET)
BITI: 25.80 (-0.71), ACOR: 27.07 (-0.45)
Final Results of the Subsequent Offer Period of Acorda Therapeutics' Tender Offer for All of the Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp.
BusinessWire - Mon May 02, 8:02AM CDT
The subsequent offer period under the voluntary public tender offer by Acorda Therapeutics, Inc. (Nasdaq:ACOR) ("Acorda" or the "Offeror" to purchase all of the issued and outstanding shares ("Shares", American Depositary Shares ("ADSs", stock options, share units and warrants (such securities, collectively, the "Equity Interests" in Biotie Therapies Corp (Nasdaq Helsinki: BTH1V; Nasdaq:BITI) ("Biotie" or the "Company" that are not owned by Biotie or any of its subsidiaries (the "Tender Offer" commenced on 14 April 2016 and expired on 28 April 2016 (the "Subsequent Offer Period".
BITI: 25.80 (-0.71), ACOR: 27.07 (-0.45)
Acorda (ACOR) Q1 Earnings Decline Y/Y, Ampyra in Focus
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 9:50AM CDT
Investor focus will remain on the patent challenges being faced by Acorda's (ACOR) key product, Ampyra.
BIIB: 246.13 (-4.33), EBS: 42.30 (-1.19), BITI: 25.80 (-0.71), ACOR: 27.07 (-0.45)
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), IDRA: 1.50 (-0.07), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)
Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 81.10 (-1.84), ALXN: 135.61 (-2.63), AEGR: 1.37 (-0.13), ACOR: 27.07 (-0.45)
Acorda Presents Phase 1 Data on CVT-427 for Acute Treatment of Migraine at 58th Annual Scientific Meeting of the American Headache Society
BusinessWire - Thu Jun 09, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced pharmacokinetic (PK) data from a Phase 1 study of CVT-427, an inhaled formulation of zolmitriptan, resulting in increased bioavailability and faster absorption compared to oral and nasal administration of the same active ingredient in healthy adults. The data on CVT-427, an investigational agent under development for the acute treatment of migraines, will be presented on June 10th, 2016, at the 58th Annual Scientific Meeting of the American Headache Society, in San Diego, CA.
ACOR: 27.07 (-0.45)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), IDRA: 1.50 (-0.07), RTRX: 17.40 (-0.30), LGND: 113.74 (-1.34), ACOR: 27.07 (-0.45)
Celldex (CLDX) Presents Phase II Melanoma Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 9:45AM CDT
Celldex Therapeutics (CLDX) announced positive phase II data evaluating CDX-301 and CDX-1401 in patients with malignant melanoma at ASCO.
ANIP: 52.05 (-1.64), CLDX: 4.12 (-0.20), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)
Acorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference
BusinessWire - Tue May 31, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 7 at 2:00pm PT (5:00pm ET).
ACOR: 27.07 (-0.45)
The Medicines Co. Carbavance TANGO 1 Study Enrolled
Zacks Equity Research - Zacks Investment Research - Fri May 27, 1:45PM CDT
The Medicines Company (MDCO) announced that it has completed enrollment in the phase III TANGO 1 study on Carbavance for the treatment of cUTI.
MDCO: 37.26 (-1.22), ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)
Alkermes Begins Phase I Study on Immuno-Oncology Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 10:30AM CDT
Alkermes (ALKS) announced the initiation of a phase I study on its immuno-oncology candidate ALKS 4230 for the treatment of solid tumors
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45), ALKS: 42.65 (-1.17)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 91.49 (-1.00), HZNP: 17.88 (-0.65), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25), ACOR: 27.07 (-0.45), BIOD: 0.34 (unch), XNPT: 7.00 (unch)
Acorda Shelves Development of Epilepsy Treatment, Plumiaz
Arpita Dutt - Zacks Investment Research - Mon May 23, 6:39AM CDT
Acorda's (ACOR) decision to terminate the development of Plumiaz was based on data from ongoing studies.
HSKA: 35.56 (-0.56), ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)
Acorda to Discontinue Development of PLUMIAZ for Treatment of Epilepsy Seizure Clusters
BusinessWire - Fri May 20, 5:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will discontinue development of PLUMIAZ(TM) (diazepam) Nasal Spray, an investigational therapy being studied for the treatment of seizure clusters in people with epilepsy. Data from the ongoing clinical trials do not demonstrate its bioequivalence to Diastat(R) rectal gel, needed to re-file the New Drug Application (NDA) under section 505(b)(2). Specifically, the data demonstrated unexpectedly lower nasal mucosa absorption of diazepam in persons with epilepsy compared to studies in healthy volunteers.
ACOR: 27.07 (-0.45)
Biotie Therapies Corp. to Delist Its American Depositary Shares from the Nasdaq Global Select Market
BusinessWire - Wed May 18, 8:00AM CDT
Biotie Therapies Corp. ("Biotie"
today announces that its Board of Directors has resolved to voluntarily delist its American Depositary Shares ("ADSs", each representing 80 Biotie ordinary shares with no nominal value ("Shares", from the NASDAQ Global Select Market ("NASDAQ US". ACOR: 27.07 (-0.45)
BIOTIE CANCELS ALL TREASURY SHARES HELD BY THE COMPANY
Globe Newswire - Wed May 18, 1:02AM CDT
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 18 May 2016, at 9.00 a.m. (EET)
BITI: 25.80 (-0.71), ACOR: 27.07 (-0.45)
Dry Powder Inhaler Devices Medical Devices Pipeline Assessment, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Acorda Therapeutics, Bespak Europe, Nekta - Research and Markets
BusinessWire - Fri May 13, 9:31AM CDT
Research and Markets has announced the addition of the "Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2016" drug pipelines to their offering.
ACOR: 27.07 (-0.45)
Aegerion Enters into Settlement Agreement with DoJ and SEC
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:36AM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) announced that it has reached preliminary agreements with the U.S. DoJ and staff of the SEC.
ABT: 38.40 (-0.47), AEGR: 1.37 (-0.13), ACOR: 27.07 (-0.45), SNY: 39.41 (-1.45)
Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More
Zacks Equity Research - Zacks Investment Research - Tue May 10, 8:45AM CDT
With the Q1 cycle nearing its end, the earnings picture is becoming increasingly clear. While the going looked tough at the onset of the last month, that scenario has changed over the past few weeks.
CRME: 4.96 (-0.38), JNJ: 117.01 (+0.01), EARS: 3.27 (-0.13), GILD: 84.45 (-1.32), BITI: 25.80 (-0.71), BPTH: 2.43 (-0.01), AMGN: 154.78 (-2.00), ACRS: 21.97 (+0.40), ACOR: 27.07 (-0.45), NVS: 78.94 (-1.57)
Acorda Therapeutics Named One of the Best Places to Work for in New York
BusinessWire - Wed May 04, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the best companies to work for in New York, based on an independent survey by the Best Companies Group (BCG). This is the sixth consecutive year Acorda was among the top 10 best employers in the state.
ACOR: 27.07 (-0.45)
FINAL RESULTS OF THE SUBSEQUENT OFFER PERIOD OF ACORDA'S TENDER OFFER FOR ALL SECURITIES IN BIOTIE
Globe Newswire - Mon May 02, 8:40AM CDT
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 2 May 2016, at 4.40 p.m. (EET)
BITI: 25.80 (-0.71), ACOR: 27.07 (-0.45)
Final Results of the Subsequent Offer Period of Acorda Therapeutics' Tender Offer for All of the Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp.
BusinessWire - Mon May 02, 8:02AM CDT
The subsequent offer period under the voluntary public tender offer by Acorda Therapeutics, Inc. (Nasdaq:ACOR) ("Acorda" or the "Offeror"
to purchase all of the issued and outstanding shares ("Shares", American Depositary Shares ("ADSs", stock options, share units and warrants (such securities, collectively, the "Equity Interests" in Biotie Therapies Corp (Nasdaq Helsinki: BTH1V; Nasdaq:BITI) ("Biotie" or the "Company" that are not owned by Biotie or any of its subsidiaries (the "Tender Offer" commenced on 14 April 2016 and expired on 28 April 2016 (the "Subsequent Offer Period". BITI: 25.80 (-0.71), ACOR: 27.07 (-0.45)
Acorda (ACOR) Q1 Earnings Decline Y/Y, Ampyra in Focus
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 9:50AM CDT
Investor focus will remain on the patent challenges being faced by Acorda's (ACOR) key product, Ampyra.
BIIB: 246.13 (-4.33), EBS: 42.30 (-1.19), BITI: 25.80 (-0.71), ACOR: 27.07 (-0.45)
